Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 4INTERVENTIONAL

Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This is a multi-site, multi-disciplinary, Phase-4 two-arm cluster-randomised non-inferiority trial in Burkina Faso and Mali to evaluate the effectiveness and real-life impact of a novel integrated delivery strategy of the R21 malaria vaccine alongside SMC among children in areas with highly seasonal malaria transmission. In this study, a cluster is defined as the catchment area of a health centre. Clusters will be randomised to receive either year-round age-based routine EPI vaccination for children aged 5-36 months ("Routine EPI Vaccination") in Burkina Faso or an annual campaign of the 3-dose primary series in children aged 5-36 months prior to the malaria season and SMC delivery (''Routine Pre-SMC vaccination'') in Mali versus an annual campaign of the 3-dose primary series aligned with SMC distribution in children aged 3-59 months ("Integrated SMC Vaccination") in each country. Effectiveness will be assessed in terms of clinical malaria, vaccine coverage, acceptability, feasibility, and cost-effectiveness. Malaria incidence will be determined using routine surveillance activities for clinical malaria detection and reporting in each country. Cross-sectional surveys will be conducted to determine the prevalence of parasitaemia in the communities. In addition, the acceptability, feasibility, coverage and cost-effectiveness of the different delivery systems of R21/Matrix-M will be assessed.

Who May Be Eligible (Plain English)

Who May Qualify: Control arms : - Children aged 5-36 months in Burkina Faso and Mali at the time of first study vaccination; - Resident in the catchment area of a health centre assigned to the control arm; - Willingness to comply with the study procedures; - Written willing to sign a consent form from Parent/Guardian. Intervention arms : - Children aged 3-59 months at the time of first study vaccination; - Resident in the catchment area of a health centre assigned to the intervention arm; - Willingness to comply with the study procedures; - Written willing to sign a consent form from Parent/Guardian. Who Should NOT Join This Trial: 1. History of allergic disease or reactions likely to be exacerbated by any component of the Vaccines; 2. Any history of anaphylaxis in relation to vaccination; 3. Known chronic illness; 4. Any other significant disease, disorder or situation which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial; 5. History of vaccination with another malaria vaccine. - Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion criteria: Control arms : * Children aged 5-36 months in Burkina Faso and Mali at the time of first study vaccination; * Resident in the catchment area of a health centre assigned to the control arm; * Willingness to comply with the study procedures; * Written informed consent from Parent/Guardian. Intervention arms : * Children aged 3-59 months at the time of first study vaccination; * Resident in the catchment area of a health centre assigned to the intervention arm; * Willingness to comply with the study procedures; * Written informed consent from Parent/Guardian. Exclusion Criteria: 1. History of allergic disease or reactions likely to be exacerbated by any component of the Vaccines; 2. Any history of anaphylaxis in relation to vaccination; 3. Known chronic illness; 4. Any other significant disease, disorder or situation which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial; 5. History of vaccination with another malaria vaccine. -

Treatments Being Tested

OTHER

Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months

in the intenvention arm, the children will get the vaccine R21 Matrix M together with the CPS

Locations (2)

Institut de Recherche en Sciences de la Santé, Direction Régionale du Centre-Ouest
Ouagadougou, Burkina Faso
University of Sciences Techniques and Technologies of Bamako
Bamako, Mali